Charles River Laboratories International, Inc. CRL
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Charles River Laboratories International, Inc. (CRL) Book value per share
Charles River Laboratories International, Inc.'s book value per share at the end of fiscal 2025 was 64.0×, down 5.22% from 67.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 59.3×. Over the past ten years it has ranged from 15.9× (fiscal 2015) to 70.3× (fiscal 2023); the current reading is higher than 82% of that period. Charles River Laboratories International, Inc. ranks 8th of 52 Diagnostics & Research companies by book value per share.
Book value per share, annual
Annual
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 64.0× | (5.22%) |
| FY2024 | 67.5× | (4.04%) |
| FY2023 | 70.3× | 19.86% |
| FY2022 | 58.7× | 16.21% |
| FY2021 | 50.5× | 18.10% |
| FY2020 | 42.7× | 27.19% |
| FY2019 | 33.6× | 22.10% |
| FY2018 | 27.5× | 24.78% |
| FY2017 | 22.1× | 23.59% |
| FY2016 | 17.8× | 12.52% |
Quarterly
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 59.3× | (1.54%) |
| Mar 2026 | 60.2× | (5.89%) |
| Dec 2025 | 64.0× | (7.71%) |
| Sep 2025 | 69.3× | 1.38% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| ICLR ICON PLC compare | 122× |
| LH Labcorp Holdings Inc. compare | 105× |
| DGX Quest Diagnostics Incorporated compare | 70.4× |
| RVTY Revvity Inc. compare | 64.8× |
| CRL Charles River Laboratories International, Inc. | 59.3× |
| QGEN QIAGEN N.V. compare | 16.3× |
| MEDP Medpace Holdings, Inc. compare | 15.4× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| GH Guardant Health, Inc. compare | −1.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- The full statement